

30 number of tables: 3 Supplementary Tables

31 **Abstract**

32 *Rationale:* The recently discovered meningeal lymphatic vessels (mLVs) have been proposed to be
33 the missing link between the immune and the central nervous systems. The role of mLVs in
34 modulating the neuro-immune response following a brain injury, however, has not been analyzed.
35 Parenchymal T lymphocyte infiltration has been previously reported as part of secondary events
36 after traumatic brain injury (TBI), suggestive of an adaptive neuro-immune response. The
37 phenotype of these cells has remained mostly uncharacterized. In this study, we identified the
38 subpopulations of T cells infiltrating the perilesional areas 30 days post-injury (an early-chronic
39 time point). Furthermore, we analyzed how the lack of mLVs affects the magnitude and the type of
40 immune response in the brain after TBI. *Methods:* TBI was induced in K14-VEGFR3-Ig transgenic
41 (TG) mice or in their littermate controls (WT; wild type), applying a controlled cortical impact
42 (CCI). One month after TBI, T cells were isolated from cortical areas ipsilateral or contralateral to
43 the trauma and from the spleen, then characterized by flow cytometry. Lesion size in each animal
44 was evaluated by MRI. *Results:* In both WT and TG-CCI mice, we found a prominent T cell
45 infiltration in the brain confined to the perilesional cortex and hippocampus. The majority of
46 infiltrating T cells were cytotoxic CD8⁺ expressing a CD44^{hi}CD69⁺ phenotype, suggesting that
47 these are effector resident memory T cells. K14-VEGFR3-Ig mice showed a significant reduction of
48 infiltrating CD4⁺ T lymphocytes, implying that mLVs are important in establishing a proper neuro-
49 immune response. Extension of the lesion (measured as lesion volume from MRI) did not differ
50 between the genotypes. Finally, TBI did not relate with alterations in peripheral circulating T cells,
51 as assessed one month after injury induction. *Conclusions:* Our data support the hypothesis that
52 mLVs are pivotal for a proper and specific neuro-immune response after TBI, which is principally
53 mediated by the resident memory CD8⁺ T cells.

54

55 **Introduction**

56 Traumatic brain injury (TBI) is among the top causes of death and disability in adult life. (Hale et
57 al., 2019, Hyder et al., 2007). At least 70 million people worldwide are estimated to incur TBIs
58 every year (Dewan et al., 2018), with the number of prevalent cases of TBI in 2016 above 55
59 million, suffering from a wide range of lifelong physical and psychological invalidities (GBD 2016
60 Neurology Collaborators, 2019).

61 TBI is defined as an alteration in brain function, or other evidence of brain pathology, caused by an
62 external force (Menon et al., 2010), which results in immediate neuronal cell death, diffuse axonal

63 injury, ischemia, and hemorrhage (McIntosh et al., 1996). These primary insults initiate a
64 progressive cascade of secondary injuries, which include macrophage infiltration (Braun et al.,
65 2017), neuro-inflammation (microglia and astrocyte activation associated with cytokine
66 production), edema formation, oxidative stress, neuronal necrosis and apoptosis, and white matter
67 atrophy (McIntosh et al., 1996). Secondary injuries can progress for years in patients and rodent
68 models of TBI, and are the causes of the neurological and psychiatric deficits associated with the
69 pathology (DeKosky et al., 1998).

70 Among secondary events following TBI, recruitment of peripheral immune cells into the brain,
71 including T lymphocytes, has been described (Daglas et al., 2019, Bai et al., 2017, Erturk et al.,
72 2016, Jin et al., 2012). Two distinct waves of infiltrating CD3+ T cells have been reported in the
73 injured brain. First, a massive infiltration immediately commences after trauma and peaks 3 days
74 post-injury (dpi) (Jin et al., 2012). After one month, there is a late adaptive immune response with a
75 second recruitment, which persists chronically (Erturk et al., 2016). However, the mechanisms and
76 the consequences of the activation of the adaptive immune system after TBI are still poorly
77 understood.

78 A proper immune surveillance of the brain was long disputed (Galea et al., 2007), due to the lack of
79 a classical lymphatic system within the central nervous system (CNS). However, recent studies
80 have described the presence of anatomically distinct lymphatic vessels in the meninges surrounding
81 the brain and the spinal cord. These meningeal lymphatic vessels (mLVs) preferentially drain the
82 cerebrospinal fluid into the deep cervical lymph nodes (dcLNs) (Louveau et al., 2018, Louveau et
83 al., 2015, Aspelund et al., 2015). Within these secondary lymphoid organs, brain-derived antigens
84 are presented to resident T lymphocytes, evoking different cellular fate and immune responses
85 based on the inflammatory milieu. It has been demonstrated that dcLNs play a specific role in
86 neuro-immune interaction, ensuring the protection of brain cells by promoting a non-cytotoxic
87 immune response (Thomas, D. L. et al., 2008, Harling-Berg et al., 1999, Cserr et al., 1992). From
88 this prospective, mLVs and dcLNs are essential components of a putative specific CNS lymphatic
89 system, and the mLVs could be essential in the activation of immune responses to brain insults, by
90 transporting brain-derived antigens to the dcLNs.

91 The aim of our work is to better characterize the late adaptive immune response and to decipher the
92 mechanisms underpinning the activation of T lymphocytes after TBI, focusing on the specific role
93 of mLVs in this process. In this regard, we induced a cerebral contusion in the cortex of transgenic
94 K14-VEGFR3-Ig (TG) mice that completely lack lymphatic vessels in several tissues, including the
95 meninges (Aspelund et al., 2015, Makinen et al., 2001). We examined the phenotype of T

96 lymphocytes infiltrating the perilesional cortical areas, determining the prevalence of a CD8+
97 mediated cytotoxic immune response in the TBI mice lacking the lymphatic system. One month
98 after brain injury, infiltrating T lymphocytes and circulating peripheral T cell populations in the
99 spleen were phenotyped by flow cytometry. MRI was used to evaluate and compare lesion size in
100 both transgenic animals and in their wild type (WT) littermates.

101 Our data show that the CNS immune response after TBI is specific and independent from peripheral
102 immune activation. We also demonstrate that the lack of a functional mLVs-dcLNs connection
103 alters the neuro-immune interaction after TBI, specifically dampening the CD4+ mediated immune
104 response. No differences in MRI cortical lesion were found between the two genotypes. Finally,
105 independent of genotype, infiltrating T cells present a resident memory effector phenotype,
106 supporting their role in secondary injuries after TBI.

107

108 **Material and Methods**

109 ***Mice***

110 Initial breeding pairs of K14-VEGFR3-Ig mice (C57BL/6JOLA^{Hsd} background (Makinen et al.,
111 2001)) were transferred from the University of Helsinki, and the colony was further expanded and
112 maintained at University of Eastern Finland (Kuopio, Finland). Wild type and transgenic K14-
113 VEGFR3-Ig mice used in all the experiments were littermates. Genotype screening was routinely
114 confirmed by polymerase chain reaction analysis of ear punch samples. Mixed WT and TG mice
115 were housed in standard laboratory cages (four animals per cage, until surgery) in a controlled
116 enriched environment (constant temperature, 22 ± 1 °C, humidity 50–60 %, lights on 07:00–
117 19:00), with food and water available *ad libitum* (Hutchinson et al., 2005). After TBI induction,
118 mice were kept two per cage, separated individually by a pierced partition. All animal procedures
119 were approved by the Animal Ethics Committee of the Provincial Government of Southern Finland
120 (ESAVI-2018-008787) and performed in accordance with the guidelines of the European
121 Community Council Directives 2010/63/EU.

122 ***Controlled cortical Injury (CCI) mouse model of TBI***

123 All surgical procedures were performed aseptically whenever possible. Adult, 5 month-old male
124 mice were deeply anesthetized with isoflurane (5 % for induction, 1.0-1.5 % for maintenance, in 0.5
125 L/min air; see Supplementary Table 1), injected with Carprofen (4 mg/Kg; s.c.) and the heads fixed
126 to a stereotaxic frame (Kopf, Tujunga, USA). The scalp was shaved and then scrubbed (3x) with

127 alternating Betadine (povidone-iodine 10 %) and 70 % ethanol, then local anesthesia of 2%
128 Xylocain gel was applied. After skull exposure, a 5 mm circular craniotomy was manually drilled
129 over the left parieto-temporal cortex, with the posterior edge of the craniotomy opposed to the
130 lambdoid suture and the right edge to the sagittal suture. In order to reduce heating during manual
131 craniotomy, the skull was irrigated with cold 0.9 % saline solution. The carved bone was carefully
132 removed, without disrupting the underlying dura, and placed in 1 % Betadine solution. Thereafter,
133 the animal was disconnected from isoflurane anesthesia for 5 min (stage 3 plane 1 according to
134 Guedel's classification (Guedel, 1927)), and CCI was induced using an electromagnetic stereotaxic
135 impact actuator (ImpactOne, Leica, Richmond, VA, USA). The 3 mm blunt tip of the impactor was
136 adjusted to the center of the exposed dura perpendicular to the brain surface, and the impact was
137 administered at a depth of 0.5 mm, speed of 5.0 m/s, and dwell time of 100 ms. The total duration
138 of the craniotomy procedure including anesthesia induction was 35-40 min (Supplementary Table
139 1). After the impact, the mouse was reconnected to the isoflurane system and the skull secured with
140 bone cement (Selectaplus + Palacos R+G 50/50). The scalp was sutured and treated with Cicatrene
141 powder (Neomycin + Bacitracin) and Terramycin spray (Oxytetracycline). The total duration of
142 post-impact surgery was 10 min. The mice were injected i.p. with 1 mL pre-warmed sterile saline
143 (35 °C) and allowed to fully recover in an incubator at 32 °C. Mice were followed for the
144 subsequent 48 h for any signs of illness or distress, in which case Carprofen was administered.
145 Daily examination was performed for general health/mortality, and moribundity for the rest of the
146 study. No mortality was observed.

147 Craniotomy-related neuroinflammation has been previously reported in this model and the
148 craniotomy itself can be considered a form of mild brain trauma (Sashindranath et al., 2015, Cole et
149 al., 2011). Moreover, CCI is a model of penetrating injury, involving dura damage, which has a
150 severity that bypasses the possible effect of meningeal inflammation related to the craniotomy. The
151 aim of our study is to characterize the adaptive immunity in response to a moderate TBI. It is not to
152 analyze how differences in trauma severity can affect the neuro-immune response. In compliance to
153 the 3R principle, we excluded the sham-operated animals and used naïve mice not exposed to the
154 surgical procedure as proper controls.

155 *In vivo MRI and lesion volume definition*

156 MRI data were acquired 21 days after TBI induction in a 7T horizontal magnet (Bruker
157 Pharmascan, Ettlingen, Germany). Images were acquired using a four-channel mouse brain surface
158 coil, a 3D T2-weighted Fast Spin-Echo sequence (RARE, repetition time 1.5 s, effective echo time
159 48 ms, 16 echoes per excitation) with 100 µm isotropic resolution (field of view 25.6 mm x 128.8

160 mm x 9.6 mm; acquisition matrix 128 x 256 x 96). Scans were performed with the mouse under 1.0-
161 1.5 % maintenance isoflurane anesthesia (70/30 N₂O/oxygen gas mixture, 1 L/min). The average
162 acquisition time was 40 min, including anesthesia induction. A pressure sensor was used to monitor
163 the respiratory rate, and respiratory gating was used to minimize motion artifacts.

164 T2-weighted images were used to evaluate the extent of the lesion (Figure 6 and Supplementary
165 Figure 4). Regions of interest (ROIs) were outlined for volumetric analysis, avoiding the brain-skull
166 interface and ventricles, throughout the entire extension of the brain (excluding olfactory bulbs and
167 cerebellum). Lesion was defined as cortical/subcortical areas with hyper-intense signal (cystic
168 lesion) and/or signal void areas (tissue cavity) from T2-weighted images (Immonen, R. et al., 2010,
169 Immonen, R. J., Kharatishvili, Niskanen et al., 2009). Volumes of the lesion and of the ipsilateral
170 and contralateral hemispheres were measured using Aedes (<http://aedes.uef.fi>), an in-house written
171 MatLab program (MathWorks, Natick, MA). The lesion volume and the volumes of ipsilateral and
172 contralateral healthy hemispheres were calculated from 80 consecutive slices in the coronal plane
173 and adjusted in the sagittal plane (66 slices) and in the axial plane (99 slices) with a volume
174 resolution of 200 x 500 x 100 μ m.

175

176 ***Quantification of brain contusion area and brain atrophy***

177 Measured volumes from MRI analysis were used to quantify the volume of the brain contusion and
178 the brain atrophy, as previously described (Dhungana et al., 2013, Shuaib et al., 2002). The relative
179 percentage of infarct volume was calculated using the following formula: contusion volume =
180 (volume of contralateral hemisphere – (volume of ipsilateral hemisphere – measured lesion
181 volume))/volume of contralateral hemisphere. Brain atrophy was determined with the following
182 formula: atrophy = (volume of ipsilateral hemisphere – volume of contralateral hemisphere)/volume
183 of contralateral hemisphere.

184 Analysis was performed blinded to the study groups. The contusion volume was measured from 22
185 TBI mice from the following experimental groups: wild type (WT)-CCI, n = 13; and K14-
186 VEGFR3-Ig (TG)-CCI, n = 9.

187 ***Cell isolation of leukocytes***

188 Thirty days after TBI induction, mice were anesthetized with an overdose of Avertin (Sigma, St.
189 Louis, MO, USA) then transcardially perfused with ice-cold heparinized saline. Brains were

190 collected and placed on ice in calcium and magnesium-free Hanks Balanced salt solution (HBSS)
191 with 25 mM HEPES (both from Sigma).

192 Based on the analysis of MRI, we defined *a priori* the mean extension of the lesion and of the
193 perilesional areas for all the TBI mice. Brains were sliced using a 1 mm scored matrix (Zivic
194 Instruments, Pittsburgh, PA, USA): 6 mm thick coronal cut encompassing the lesion area was split
195 along the central sagittal axis into left injured and right uninjured sides. Cortical areas enclosed
196 between the rhinal and the sagittal sulci, and the corresponding hippocampi, were further isolated,
197 pooled together, and placed in HBSS+HEPES. From the injured sides, penetrated cortical areas
198 were visually identified (lesion area - Supplementary Figure 1) and carefully excised along the
199 lesion ridge to pick only the perilesional cortex for further purification of leukocytes.

200 Brain samples were minced with scissors and then incubated at 37 °C on a roller for 30 min in
201 digest buffer containing 1.25 mg/mL Collagenase Type 4 (Worthington, Lakewood, NJ, USA) and
202 100 U/mL DNaseI (Sigma) in DMEM with GlutaMAX (Gibco Thermo Fisher Scientific, Waltham,
203 MA, USA). Samples were filtered through a 100 µm cell strainer (Corning, Weisbaden, Germany),
204 and centrifuged at 600 x g for 5 min. Myelin debris was removed using Debris Removal Solution
205 (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Briefly,
206 cells were resuspended in ice-cold Dulbecco's phosphate buffered saline (D-PBS, Sigma) with
207 Debris Removal Solution, then overlaid with ice-cold D-PBS and centrifuged at 2500 x g for 10
208 min at 4 °C. Supernatant including myelin layer was carefully removed leaving the clear phase and
209 the pellet. Samples were washed in ice-cold D-PBS, centrifuged at 600 x g for 10 min at 4 °C, and
210 the recovered pellets were stained directly for flow cytometry.

211 Spleens and dcLNs were separately collected in ice-cold HBSS+HEPES and each processed by
212 crushing through a 70 µm cell strainer (Corning). dcLNs were washed with ice-cold D-PBS
213 containing 1% bovine serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid (EDTA),
214 centrifuged 500 x g for 10 min and resuspended in RPMI-1640 (all from Sigma). Crushed spleens
215 were washed with ice-cold HBSS+HEPES, centrifuged 500 x g for 5 min before red blood cells
216 were lysed in 1X PharmLyse (BD Biosciences, San Jose, CA USA) for 8 min at room temperature
217 (RT). Lysed cells were washed with HBSS+HEPES, centrifuged as above, resuspended in RPMI-
218 1640 (Sigma), and counted on a Bürker grid hemocytometer.

219 *Flow Cytometry staining and analysis*

220 Spleen cells (500 000 per mouse), and total cells isolated from dcLNs and brain were each stained
221 separately. Cells were first washed with D-PBS, and centrifuged at 400 x g for 5 min. The

222 supernatant was removed, and then Zombie NIR fixable viability dye (1:1000 BioLegend, San
223 Diego, CA, USA) was added for 15 min at RT. Without washing, CD16/32 FcR block (5 µg/ml, BD
224 Biosciences) was added followed by the appropriate antibody mix. Antibodies used: TCRβ PE-Cy7
225 (1:100 or 1:200 clone H57-597), CD44 PE (1:300 clone IM7) (both BioLegend); CD8a APC-R700
226 (1:150 or 1:200, clone 53-6.7), CD69 BV421 (1:100, clone H1.2F3), CD25 BB515 (1:150, clone
227 PC61) (BD Biosciences); CD4 FITC (1:500, clone RM4-5), CD4 eFluor506 (1:500, clone RM4-5),
228 CD8 PerCP eFluor710 (1:300, clone 53-6.7), CD44 APC (1:300 or 1:400, clone IM7), FoxP3 (1:40,
229 clone FJK-16s) (eBioscience Thermo Fisher Scientific, Waltham, MA, USA); CD69 APC (1:20,
230 clone H1.2F3, Miltenyi Biotech). All antibodies were used at titers determined empirically under
231 experimental conditions.

232 Cells were incubated for 30 min at 4 °C. Afterwards, samples were washed twice in HBSS with 1 %
233 FBS and then run on FACSARIAIII (BD Biosciences) equipped with 488 and 633 nm lasers, or on
234 CytoFLEX S (Beckmann Coulter) equipped with 405, 488, 561 and 638 nm lasers, both with
235 standard configuration. Compensations were made using OneComp and UltraComp Beads for
236 antibody fluorescence (eBioscience Thermo Fisher Scientific) and ArC amine reactive beads for
237 viability dye (Molecular Probes, Eugene, Oregon, USA). Fluorescent-Minus-One (FMO) controls
238 were made to ensure gating. These control samples contained all antibodies except one to display
239 fluorescent spreading error of compensated data in each channel (Roederer, 2002). Data were
240 analyzed using FCSEXPRESS v5 (Denovo Software, Los Angeles, CA, USA) and FlowJo v10.4
241 (Treestar, Portland, OR, USA). The gating strategy used for the flow cytometry analysis of brain-
242 isolated immune cells is reported in Figure 1.

243 ***CD3 immunohistochemical staining***

244 Three mice per genotype were injured and sacrificed 30 days after TBI for the
245 immunohistochemical (IHC) estimation of T lymphocyte localization in the brain. Mice were
246 transcardially perfused with ice-cold NaCl 0.9 % followed by 4 % PFA. Brains were dissected and
247 post-fixed in 4 % PFA by immersion for 24 h at 4 °C. Thereafter, specimens were cryoprotected by
248 incubation in 20 % glycerol (in 0.02 M potassium phosphate-buffered saline (KPBS), pH 7.4) for
249 48 h, frozen in N-pentane (3 min at -60 °C), and stored at -70 °C until sectioning. Frozen coronal
250 sections were cut 25 µm with a sliding microtome, and collected in solution containing 30 %
251 ethylene glycol, 25 % glycerol in 0.05 M phosphate buffer (PB) and stored at -20 °C until further
252 processing. Three sections per brain (approx. 700 µm apart, encompassing the antero-posterior
253 extension of the lesion,) were used to estimate the localization of CD3+ infiltrating T lymphocytes

254 by IHC. Floating sections were washed in three changes of 1X PBS before being incubated for 1 h
255 at RT in blocking solution (2 % normal goat serum, 1 % bovine serum albumin (BSA) 0.1 % Triton
256 X-100 and 0.05 % Tween20 in PBS). Sections were incubated overnight at 4°C with rat anti-mouse
257 CD3ε in staining buffer PBS with 1 % BSA and 0.05 % Triton X-100 (1:500, clone 17A2,
258 eBioscience Thermo Fisher Scientific). After washing 3x with PBS, sections were incubated with
259 secondary antibody Alexa Fluor 647- or Alexa Fluor 488-conjugated goat anti-rat secondary
260 antibody in above staining buffer for 1 h at RT (1:500, both Thermo Fisher Scientific). Finally, the
261 sections were washed 3x in PBS and 10 min in 1X PB, and mounted on Superfrost Plus slides
262 (Thermo Scientific) with Vectashield (Vector Laboratories, Burlingame, CA, USA). Panoramic
263 photomicrographs of the stained sections were captured using 20X objective with a fluorescence
264 microscope (Zeiss Observer.Z1), and high-resolution Z-stack images were captured using 20X
265 objective with a confocal microscope (Zeiss LSM710). ZEN 2012 software (Carl Zeiss GmbH) was
266 used for image processing.

267 ***MAP2, NeuN and GFAP staining and analysis***

268 Three sections located at bregma level +0,02 mm, -2,06 mm and -4,04 mm (corresponding to the
269 anterior and posterior edges and to the center of the lesion site) were selected from the previously
270 sliced brains and stained for the Microtubule-Associated Protein 2 (MAP2; neuronal dendrites), the
271 neuronal antigen NeuN, and the Glial Fibrillary Acidic Protein (GFAP; Type III intermediate
272 filaments in astrocyte). For immunofluorescence procedure, sections were washed and blocked in
273 blocking solution (4 % BSA, 0,2 % Triton X-100 in PBS) for 1 h at RT, followed by overnight
274 incubation at 4 °C with the following primary antibodies diluted in blocking solution: mouse anti-
275 GFAP (1:500, Sigma G3893), guinea pig anti-NeuN (1:500, Millipore ABN90), rabbit anti-MAP2
276 (1:300, Abcam ab32454). After washing in PBS, sections were incubated for 2 h at RT with
277 secondary fluorescent antibodies in blocking solution: Alexa Fluor 546-conjugated goat anti mouse
278 (1:250), Alexa Fluor 488-conjugated goat anti rabbit (1:250), Alexa Fluor 633-conjugated goat anti
279 guinea pig (1:200 all from Invitrogen, Thermo Fisher Scientific). Next, sections were washed in
280 PBS before being mounted onto glass slides and coverslipped using Fluoromount-G (Thermo Fisher
281 Scientific).

282 Image acquisition was performed using Zeiss Axio Observer Z1 microscope, equipped with a Zeiss
283 AxioCam MR R3 camera, mounting a 10x lens to obtain images from whole-brain sections.

284 Image analysis was performed using ImageJ software. Regions of interest (ROIs) were manually
285 selected on images taken from each stained section. After background subtraction, the mean gray
286 value was measured within each ROI (Clement et al., 2019).

287

288 **Statistical analysis**

289 *Data exclusion criteria* – We conducted 9 independent experiments, where a total of n = 16 “WT
290 CCI”; n = 12 “WT naïve”; n = 13 “TG CCI” and n = 10 “TG naïve” mice have been analyzed.

291 Before statistical analysis, brain-derived samples were checked for their quality, based on total T
292 cell recovery. Each sample has been considered independently, and we evaluated the T cell viability
293 and the total number of T cells recovered. Brain samples where T cell viability was below 75 % or
294 the total number of live T cells was below 100 counts were *a priori* excluded from the analyses.

295 Considering two genotypes (WT and TG) and three experimental conditions (T cells infiltrating the
296 brain tissue ipsilateral to the lesion – “ipsi”; T cells infiltrating the tissue contralateral to the lesion –
297 “contra”, and T cells from naïve brain tissue – “naïve”), a total of n = 12 “WT ipsi”; n = 7 “WT
298 contra”; n = 5 “WT naïve”; and n = 10 “TG ipsi”; n = 7 “TG contra”; n = 9 “TG naïve” were finally
299 used for statistical analyses.

300 T cell viability > 90 % was used for the quality requirement of spleen and dcLN samples.
301 Moreover, we excluded spleen samples presenting more than 50 % of necrotic tissue (defined as
302 dark red non-perfused area in the spleen). Considering two genotypes (WT and TG) and two
303 experimental conditions (CCI and naïve), a total of n = 13 “WT CCI”; n = 12 “WT naïve”; and n =
304 11 “TG CCI”, n = 9 “TG naïve” spleens were used for subsequent statistical analyses. Deep cervical
305 lymph nodes have been analyzed in n = 4 “WT CCI” and n = 6 “TG CCI” mice.

306 *Statistical analysis of brain- and dcLNs-related data* – Due to the small amount of T lymphocytes
307 in naïve brains, brain samples were fully acquired on the flow cytometer, and for each population
308 we analyzed both the absolute counts and the percentage referred to the respective parent
309 population. Statistic models were applied considering the nature of our data (counts or percentages)
310 and the experimental groups analyzed. A binomial negative regression was applied to assess
311 statistical differences in the counts of total T cells, of CD4+, and of CD8+ cells between the two
312 genotypes or within the same genotype between independent data. The binomial negative regression
313 considered both genotype and treatment and their interaction. Because data from ipsi and
314 contralateral brain sides are dependent within the same genotype, a linear mixed model was used to

315 evaluate the differences in the total number of CD4+ and CD8+ T lymphocytes between “WT ipsi”
316 vs. “WT contra” or “TG ipsi” vs. “TG contra”. As the data were not normally distributed (Shapiro-
317 Wilk test p -value < 0.05), statistical differences between independent data in CD4+ and CD8+ T
318 cell populations (expressed as percentage of T cells), as well as in the percentages of respective
319 subpopulations expressing CD44 and/or CD69 antigens, were analyzed performing the Kruskal
320 Wallis test. Dependent data within the same genotype (ipsi vs. contra) were analyzed performing
321 the paired samples Wilcoxon signed ranked test. In all tests, Bonferroni correction was used to
322 adjust p -values in multiple comparison.

323 *Statistical analysis of data from spleen* – All data from spleen are expressed as percentage of the
324 parent population. After establishing the normal distribution of the data (as well as skewness and
325 kurtosis by D’Agostino K-squared test), statistical differences were analyzed performing the
326 Kruskal Wallis test or the paired samples Wilcoxon signed ranked test, depending on the nature of
327 the data (independent or dependent), followed by Bonferroni adjustment.

328 *Statistical analysis of MRI data* – The differences in contusion volume and in brain atrophy were
329 analyzed performing the Kruskal Wallis test. Correlation between TBI-related tissue loss and infarct
330 volume was analyzed by Pearson linear regression, after checking for normal distribution of data as
331 described above.

332 Statistical analyses were performed using R v3.5.3 software/computing environment (The R
333 foundation for statistical computing). All software packages (MASS, psych, agricolae, multcomp
334 and lme4) (Mendiburu, 2019, Revelle, 2018, Bates et al., 2015, Hothorn et al., 2008, Venables and
335 Ripley, 2002) were taken from the Comprehensive R Archive Network mirror sites (CRAN;
336 <http://CRAN.R-project.org/package=boot>). Significance was accepted at the level of $p < 0.05$.

337 **Results**

338 **T cells preferentially infiltrate the cortical areas ipsilateral to the lesion**

339 The presence of infiltrating T lymphocytes in the parenchyma is a signature of brain lesion. At a
340 chronic time point after TBI, we estimated T cell presence in the area of injury and in other brain
341 areas not directly affected by the penetrating injury. For this purpose, we stained brain sections of
342 both WT and TG mice at 30 days post-injury (dpi) for the presence of CD3, a specific marker of T
343 lymphocytes. As expected, T cells are massively present within the boundaries of the injured area
344 (Figure 2A, B; Supplementary Figure 1B). CD3+ cells are also spread throughout the cortical
345 parenchyma, both in proximity to the lesion core (Figure 2C) and in more distal areas ipsilateral to

346 the lesion along the cortical layers. Positive immunostaining was also found along the corpus
347 callosum (Figure 2D; Supplementary Figure 1B) while a minor presence of T cells was observed in
348 the striatum, the hippocampus, and the thalamus ipsilateral to the lesion (Figure 2A). Dim CD3+
349 signal was present in the contralateral hemisphere, indistinguishable from non-injured mice (data
350 not shown). There was no difference in T cell distribution between WT and TG mice. Unevenly
351 scattered T cells (Figure 2E) and T cell clusters (Figure 2C, D) were both observed within the
352 parenchyma, suggesting the presence of clonal expansion of activated T cells.

353 Next, we decided to quantify and characterize the populations of infiltrating T lymphocytes using
354 flow cytometry, focusing on the neo-cortical areas (cortices and hippocampi), excluding the lesion
355 area, which is characterized by a dysregulated entrance of immune cells (Fee et al., 2003).

356 Thirty days after brain trauma induction in TG and littermate WT mice, leukocytes were purified
357 separately from the perilesional and the contralateral cortices (or from the cortex of both WT and
358 TG naïve mice). T cells were identified by staining for T cell receptor (TCR β) and the presence of
359 the co-receptors CD4 and CD8. The acquired count of live T cells in the different experimental
360 conditions is reported in Figure 3. A significant ~10-fold increase of infiltrating T cells was found
361 in both WT (median = 1449; Q3-Q1 = 1692) and TG (median = 1741; Q3-Q1 = 892) mouse brains
362 in the perilesional cortices, compared to corresponding naïve non-injured mice (WT naïve: median
363 = 242; Q3-Q1 = 105; TG naïve: median = 197; Q3-Q1 = 66; for statistical analysis, see Figure 3A).
364 In the cortices contralateral to the lesion, the number of TCR β + cells was no different from naïve
365 brains (WT contra: median = 201; Q3-Q1 = 84; TG naïve: median = 239; Q3-Q1 = 155; for
366 statistical analysis, see Figure 3A). No genotype-related differences were observed (Figure 3A).

367 **Perilesional-infiltrating T cells have a predominant CD8+ phenotype, and the lack of a** 368 **functional lymphatic system depresses the T cell CD4-mediated response**

369 We next analyzed the CD4:CD8 ratio within the infiltrating T cells (Figure 3B) and found a
370 prevalence of CD8+ T cells in all the experimental conditions, regardless of the presence of brain
371 injury. However, limited to the perilesional cortex of TG mice, we detected a significant skew of
372 the CD4:CD8 ratio towards CD8+ cells (CD4:CD8 ratio TG ipsi = 0.097 ± 0.053 ; WT ipsi =
373 0.350 ± 0.197 ; ChiSq: 8.836, mean ranks: 5.50/13.27, $p = 8e-04$), while the ratio in the contralateral
374 cortex did not differ between the two genotypes (CD4:CD8 ratio TG contra = 0.221 ± 0.247 ; WT
375 contra = 0.456 ± 0.212 ; ChiSq: 2.469, mean ranks: 5.43/8.83, $p = 0.120$). To better understand how
376 the lack of mLVs affects the T cell-mediated neuro-immune response, we analyzed both the
377 absolute numbers of CD4 and CD8 subpopulations and their relative frequency. Data analysis

378 shows a reduction of the total number of CD4⁺ T cells infiltrating the perilesional cortices of TG
379 (median = 106; Q3-Q1 = 156) compared to WT mice (median = 245; Q3-Q1 = 218; ex. coef.: -0.82,
380 p = 0.033 TG ipsi vs. WT ipsi) (Figure 4A). No differences were observed in the absolute number
381 of infiltrating CD8⁺ T cells between the genotypes (Figure 4B). Despite no differences in absolute
382 numbers of both CD4 and CD8 populations in the contralateral cortices of injured WT and TG
383 mice, we found a significant reduction in the frequency of CD4⁺ T cells in transgenic mice (TG
384 contra = 12.04±8.47 %; WT contra = 23.59±9.52 % of T cells; ChiSq: 3.931, mean ranks:
385 5.29/9.71, p = 0.042) and a relative frequency increase of CD8⁺ T cells (Figure 4C, D). These data
386 are in line with previous studies indicating that the CD4-mediated neuro-immune response is
387 mainly induced within the dcLNs (Thomas, D. L. et al., 2008, Harling-Berg et al., 1999). As mLVs
388 are involved in the drainage of solutes from the interstitial and cerebro-spinal fluids mainly to the
389 dcLNs (Aspelund et al., 2015, Louveau et al., 2015), it is possible to conceive that their absence in
390 TG mice can affect the priming of the evoked neuro-immune response, resulting in a specific
391 impairment of CD4⁺ T cell activation. The analysis of the T cell subpopulations in the dcLNs
392 indeed revealed a marked difference between the two genotypes, supporting the role of mLVs in the
393 definition of the neuro-immune response. We found a significantly lower number of T cells in the
394 dcLNs of the TG-CCI mice (median = 73542; Q3-Q1 = 21342) compared to their WT-CCI
395 littermates (median = 220434; Q3-Q1 = 88745; p = 0.006), which had a higher frequency of CD4⁺
396 T cells (TG CCI = 63.98±5.67 %; WT CCI = 51.40±1.93 % of T cells; ChiSq: 6.545, mean ranks:
397 7.50/2.50, p = 0.0017) (Supplementary Figure 2). Within the CD4⁺ T cell subpopulation in the TG
398 mice, cells have predominantly a CD44^{hi}CD69^{neg} phenotype, while in the WT mice the predominant
399 population is CD44^{int}CD69^{neg} (Supplementary Figure 2). No differences were found in the
400 frequency of Tregs.

401 The presence of CD8⁺ T cells in the perilesional cortices (together with the presence of T cell
402 clusters, as shown by IHC staining) suggests a cytotoxic role for the infiltrating T cells at this time
403 point. However, different subpopulations of CD8⁺ and CD4⁺ T cells exist, with specific and
404 opposing functions. In addition, we characterized both the CD8⁺ and CD4⁺ subpopulations for the
405 surface expression of the antigens CD44 (a memory and activation marker) (Ponta et al., 2003,
406 Budd et al., 1987) and CD69 (an activation and tissue retention marker) (Ziegler et al., 1994). In the
407 perilesional cortex of both WT and TG mice, CD8⁺ T cells had a predominant CD44^{hi}CD69⁺
408 phenotype (69.78±22.85 % and 72.05±19.95 % of CD8⁺ T cells, in WT ipsi and TG ipsi,
409 respectively) (Figure 5A, B and Supplementary Table 2). In the mouse, the expression of CD69
410 together with high levels of CD44 define a specific subpopulation of T cells called mature resident

411 memory T cells (T_{RM}), which are generated and persist in the tissue at the site of a primary infection
412 (Topham and Reilly, 2018, Gebhardt et al., 2009) and provide a first and powerful line of adaptive
413 cellular defense.

414 The second-highest expression of a CD8⁺ subpopulation (representing 27.07 ± 26.10 % in WT and
415 25.24 ± 18.85 % in TG mice) had a CD44^{hi}CD69⁻ phenotype, characteristic of effector memory T
416 cells (Topham and Reilly, 2018). The presence of other CD8⁺ subpopulations among perilesional
417 infiltrating T cells was negligible. No genotype-related difference was found.

418 Among CD4⁺ perilesional infiltrating T cells, we found a similar frequency of CD44 and CD69
419 expressions, with a slight prevalence of CD44^{hi}CD69⁺ over CD44^{hi}CD69⁻ T lymphocytes (Figure
420 5C, D and Supplementary Table 2) in both genotypes. The overall frequency distribution of the
421 different subpopulations was identical between the two genotypes.

422 **Cortical lesion is similar in K14-VEGFR3-Ig mice and in their WT littermates**

423 Analyses of MRI images acquired 21 days after TBI induction revealed a T2 intensity increase in
424 the ipsilateral hemisphere. The increase of T2 intensity was observed in parietal-temporal cortices,
425 mainly involving the somatosensory and visual cortices (Figure 6A), expanding in a few cases to
426 the underlying hippocampus. No significant change of T2 intensity was found between the two
427 genotypes. In the WT CCI group the contusion volume was 4.53 ± 1.33 %, and 4.09 ± 2.00 % in the
428 TG CCI animals (ChiSq: 0.579, mean ranks: 8.71/10.75, $p = 0.463$) (Figure 6C). Relative brain
429 atrophy was 2.42 ± 1.09 % in WT CCI mice and 2.00 ± 1.26 % in TG CCI mice (ChiSq: 1.400, mean
430 ranks: 8.00/11.17, $p = 0.248$) (Figure 6D). Correlation between contusion volume and relative brain
431 swelling was compared in transformed data analyzed by linear regression. When considering the
432 individual values independent of the genotype, the contusion volume values significantly correlated
433 with the values of relative brain atrophy ($r = 0.57$; $p = 0.023$) (Figure 6E). No significant correlation
434 was found between the contusion volume and the mean value of the brain atrophy in both the TG
435 CCI group ($r = 0.74$; $p = 0.064$), and in the WT CCI mice ($r = 0.37$; $p = 0.331$).

436 It must be noted that we have identified the lesion size as the hyper-intense signal in the cortical
437 area observed in the T2 weighted images. Our analysis, albeit clinically relevant, suffers from a lack
438 of spatial definition and is affected mostly by the formation of the cyst at the site of injury (Maegele
439 et al., 2015, Immonen, R. et al., 2010). Therefore, subtle although significant differences in the
440 lesion size can be underestimated. However, the analysis of MAP-2 staining in the brain of the WT
441 CCI and TG CCI animals, used for the evaluation of T cell presence in the injury area, confirmed
442 the MRI results and did not show any genotype-related differences (Figure 6B).

443 **K14-VEGFR3-Ig mice present a peripheral lymphopenia, which is exacerbated after TBI**

444 Alterations of systemic immunity are frequent in TBI patients. We analyzed the levels and the
445 frequency of different T cell subpopulations in the spleen of WT and K14-VEGFR3-Ig mice, one
446 month after TBI induction. As previously described (Thomas, S. N. et al., 2012), K14-VEGFR3-Ig
447 mice show a moderate lymphopenia compared to littermate WT mice (percentage of T cells over
448 live cells in WT naïve: 37.26 ± 7.67 %; vs. TG naïve: 19.69 ± 4.96 %; ChiSq: 14.746, mean ranks:
449 5.00/15.50, $p = 1e-04$) (Figure 7A). Contrary to what was observed in the brain, the systemic
450 lymphopenia in the K14-VEGFR3-Ig genotype corresponds to a relative frequency reduction in
451 peripheral CD8⁺ T cells (TG naïve = 25.75 ± 3.61 %; WT naïve = 42.70 ± 4.17 % of T cells; ChiSq:
452 14.727, mean ranks: 5.00/15.50, $p = 1e-04$) (Figure 7B). In TG mice, but not in WT mice, we found
453 a significant reduction in the total T cell frequency after TBI (WT CCI: 33.68 ± 6.99 %; TG CCI:
454 14.23 ± 2.87 % of live cells; ChiSq: 7.695, mean ranks: 7.18/14.55, $p = 0.003$ TG CCI vs. TG naïve)
455 (Figure 7A), confirming that TG mice present an impaired immune response, which relates to the
456 alterations in the lymphatic system. Analysis of the activation markers show a different expression
457 in both CD4⁺ and CD8⁺ subpopulations between WT and TG mice, which is trauma independent.
458 Both TG naïve and TG CCI mice, indeed, showed an increased frequency of memory T cells
459 (CD4⁺CD44^{hi}CD69⁺, CD4⁺CD44^{hi}CD69⁻ and CD8⁺CD44^{hi}CD69⁺, CD8⁺CD44^{hi}CD69⁻; for
460 statistical analysis, see Supplementary Table 3) (Figure 7C, D).

461

462 **Discussion**

463 The results of this study show the effects of the deficiency of a functional CNS lymphatic system on
464 the expansion of brain-resident memory T cells as a result of a single, moderate TBI.

465 Mounting evidence implicate a sustained modulation of T lymphocyte-mediated immune response
466 following TBI, both in patients (Dressler et al., 2007, Hausmann et al., 1999, Holmin et al., 1998)
467 and in animal models of brain injuries (Bai et al., 2017, Braun et al., 2017, Erturk et al., 2016, Kelso
468 and Gendelman, 2014, Jin et al., 2012).

469 A recent publication from Daglas and colleagues characterized for the first time the T cell-mediated
470 immune response in a chronic animal model of TBI, highlighting the role of cytotoxic CD8⁺ T cells
471 in the progression of TBI pathology (Daglas et al., 2019).

472 Our data confirm the previous findings, showing a sustained accumulation of CD8⁺ T lymphocytes,
473 restricted to the non-damaged cortical areas surrounding the lesion and to the underlying corpus

474 callosum, already at 30 dpi (*i.e.*, the early chronic phases after TBI). Moreover, we expand the
475 current knowledge characterizing the phenotype of the accumulating lymphocytes as resident
476 memory T cells. This suggests a direct in-situ activation of the T cell-mediated immune response.
477 We speculate that this chronic activation is responsible for the progression of TBI pathology.

478 We also found that the congenital lack of the meningeal lymphatic system affects the polarization of
479 the TBI-elicited neuro-immune response, mainly resulting in the downregulation of CD4⁺ T cell
480 subpopulation. We finally found that the adaptive neuro-immune response is prompted even in the
481 absence of a systemic immune reaction.

482 Specifically, our findings suggest that at early chronic time points after TBI: 1) immune response in
483 the brain is principally mediated by putative T_{RM} CD8⁺ cells; 2) the CNS lymphatic system is
484 essential to modulate the specific neuro-immune response; 3) the response of peripheral T
485 lymphocytes does not correlate with the neuro-immunological state of the brain.

486 Brain trauma results in two phases of tissue injury. The primary injury which is a direct result of the
487 mechanical impact to the brain, is characterized by the activation of the innate immune response
488 and the release of excitotoxic agents. During this acute phase, a massive and dysregulated brain-
489 infiltration of T cells has been reported (Czigner et al., 2007, Clausen et al., 2007). This infiltration
490 is presumably confined to the area of the lesion, since we observed a limited number of infiltrating
491 T cells in the perilesional non-injured areas, three days after TBI induction (Supplementary Figure
492 2). A secondary tissue damage, resulting in a diffuse and long-lasting injury, usually develops after
493 months/years from the primary injury (Yasmin et al., 2019, Graham and Sharp, 2019, Immonen, R.
494 J., Kharatishvili, Grohn et al., 2009). This is characterized by additional neurodegeneration
495 developing independently from the mechanical trauma and by the formation of a fibrotic scar tissue
496 in the injured area (Fernandez-Klett and Priller, 2014) (Figure 6B). It has been recently suggested
497 that the development of secondary injuries is sustained by activated memory CD8⁺ T cells (Daglas
498 et al., 2019). In a CCI mouse model, the authors observed that the modulation of the cytotoxic
499 lymphocytes resulted in the reduction of the lesion size and in the improvement of the neurological
500 outcomes analyzed 32 weeks after injury.

501 In similar experimental conditions, we observed that CD8⁺ T lymphocytes with a CD44^{hi}CD69⁺
502 phenotype are already present in the perilesional areas (but not in the correspondent contralateral
503 cortices) one month after TBI. Since CD69 is an early marker of T cell activation (Ziegler et al.,
504 1994) and inhibits tissue egression (Gebhardt et al., 2009), our data suggest a localized activation of
505 the resident memory CD8⁺ subpopulation restricted to the areas surrounding the primary lesion. In

506 the case of TBI, CD44^{hi}CD69⁺ T_{RM} cells may represent the population designated to defend the
507 non-injured brain from possible infective agents penetrating through the lesion. However, within the
508 chronic neuro-inflammatory environment observed in the perilesional areas (Figure 6B), T_{RM} can
509 expand and activate in a dysregulated way. This contributes to the cytotoxic immune response,
510 which characterizes the chronic phases of TBI pathology. This hypothesis is supported by the data
511 reported by Daglas and colleagues (Daglas et al., 2019), indicating that the perilesional infiltrating
512 CD8⁺ T cells express and release effector cytokines (Granzyme B and IFN γ). Further studies are
513 required to determine if this adaptive response is antigen specific, and if secondary lesions are the
514 result of an autoimmune-like sequelae of events.

515 Neuro-immune responses are mainly elicited in the deep and superficial cervical lymph nodes
516 (Cserr et al., 1992, Harling-Berg et al., 1999, Thomas, D. L. et al., 2008, de Vos et al., 2002, Urra et
517 al., 2014), which are the main receivers of the mLVs. Therefore, the meningeal lymphatics
518 represent an integrated component in the neuro-immune response (Louveau et al., 2015), and their
519 functional impairment can affect its priming following TBI.

520 We addressed this hypothesis by inducing TBI in a transgenic mouse model of congenital
521 lymphedema. K14-VEGFR3-Ig mice, expressing soluble VEGFR-3-Ig (Makinen et al., 2001),
522 present alterations in the development of the lymphatic system, resulting in defective growth of
523 mLVs and in sclerotic dcLNs (Antila et al., 2017, Aspelund et al., 2015). This phenotype has been
524 confirmed in our experimental animals.

525 We found that the neuro-immune response in the K14-VEGFR3-Ig mice significantly differs from
526 the response observed in WT mice after TBI, suggesting that the functional defect in the CNS
527 lymphatic system directly affects the CNS regional immune regulation and modulates the transition
528 between the initial and secondary immune response after TBI. This hypothesis is supported by the
529 observation that the initial T cell infiltration in the perilesional areas (as determined at 3 dpi) is
530 similar in the two genotypes (Supplementary Figure 2), while at 30 dpi there is a marked decrease
531 in the CD4⁺ T cell frequency specifically in TG mice. This results in the polarization of the neuro-
532 immune response towards CD8⁺ cytotoxicity, possibly aggravating TBI outcomes as recently
533 suggested (Daglas et al., 2019).

534 Interestingly, in chronic TBI animals, the analysis of the T cell subpopulation in the CNS-draining
535 dcLNs also showed a marked difference between the two genotypes. CD4⁺CD44^{hi}CD69^{neg} T cells
536 were the predominant subpopulation in TG mice, and CD4⁺CD44^{int}CD69^{neg} T cells were
537 predominant in WT mice (Supplementary Figure 2). It has been suggested that CD4⁺CD44^{int} T

538 cells could represent the fraction of central memory T helper cells expressing IFN- γ , while
539 CD4+CD44^{hi} would preferably be effector memory cells with a Th17 phenotype (Schumann et al.,
540 2015, Gasper et al., 2014). A Th1/Th17 response has a role in CNS autoimmune diseases (Kebir et
541 al., 2007) and can enhance the cytotoxicity of CD8+ T cells (Daglas et al., 2019, Braun et al.,
542 2017). This would partially explain the direct correlation we found between the frequency of CD4+
543 T cells and the brain atrophy in TG mice but not in WT littermates (Supplementary Figure 3).
544 However, the panel of antibodies we used for T cell characterization does not allow us to
545 distinguish between the different CD4+ T helper populations (*i.e.*, Th1, Th2 or Th17) without
546 speculation.

547 Our data suggest that the functional impairment of mLVs observed in K14-VEGFR3-Ig mice
548 modulates the activation of the adaptive neuro-immune response in the downstream dLNs.
549 However, we cannot exclude other mechanisms in K14-VEGFR3-Ig mice that could modulate the
550 neuro-immune response. For instance, lymphatic vessels play a direct role in the maturation of T
551 cells, and dysfunction of the lymphatics leads to the persistence of immune cells and mediators in
552 tissues, resulting in a chronic inflammation and tissue damage (Tsunoda, 2017). It is conceivable,
553 therefore, that the congenital lack of mLVs in the K14-VEGFR3-Ig mice can affect both the type of
554 the elicited neuro-immune response and its resolution.

555 Our hypothesis that the chronic cytotoxic response is mediated by T_{RM} cells, and not by circulating
556 T lymphocytes which infiltrate the brain, has important clinical implications. TBI patients generally
557 present a delayed secondary immunodeficiency (CNS injury-induced immunodepression, CIDS)
558 (Meisel et al., 2005, Mazzeo et al., 2006), which is accompanied by an increased susceptibility to
559 systemic infections and is associated with declining neurological outcome and increased mortality.

560 Analysis of our data suggest that neuro-immune reaction can be elicited in the CNS even in the
561 presence of a systemic congenital lymphopenia (as observed in K14-VEGFR3-Ig mice), excluding a
562 correlation between the extent of brain infiltration and the level of T cells in the periphery
563 (Supplementary Figure 3). This observation has potential clinical implications, because patients
564 with CIDS could at the same time present a sustained adaptive immune response localized in the
565 brain. Immunomodulatory therapies directly targeting the brain-resident memory T cells could
566 benefit TBI patients without affecting their already compromised systemic immune system.

567 Therapeutic approaches aimed at downregulating the adaptive immune response after TBI have
568 been tested before (Weckbach et al., 2012) with no improvement on the neurological outcome,
569 leading to the hypothesis that the adaptive immune response after brain injuries can have a

570 beneficial activity (Schwartz and Raposo, 2014, Moalem et al., 1999). However, it is important to
571 note that these studies focused on the manipulation of the early wave of T cell infiltration after TBI.
572 Our findings, together with recently published data, indicate that the chronic immune response is
573 the target for the development of specific therapies for the treatment of TBI patients. This includes
574 modulating the progression of the secondary injuries and opening the way to new studies in this
575 direction.

576

577 **Limitation of the study**

578 We are aware that this study presents several limitations and further studies are needed to both
579 understand the role of CD8+ T cells in TBI pathology, and the role of mLVs in the modulation of
580 the neuro-immune response. A major limitation stems from the use of TG mice with a congenital
581 and global deficiency in the mLVs. This results in a compromised peripheral immune response, as
582 previously demonstrated (Thomas, S. N. et al., 2012) and confirmed by our spleen data. In their
583 paper, however, Thomas and colleagues reported a delayed but robust CD8-mediated response to
584 peripheral immunization and impaired tolerance. In a similar fashion, we have found an increase in
585 the CD8+ T cell response to putative brain-derived antigens. These data confirm the pivotal role of
586 lymphatic vessels in the modulation of the adaptive immune response and support the hypothesis
587 that the elicited cytotoxic response can escape the intrinsic brain tolerance. Nevertheless, this
588 hypothesis needs to be confirmed in different models that would study the effects of local partial
589 deletions of the mLVs on the activation of the neuro-immune response.

590 Another limitation of our study is the lack of difference in lesion size between K14-VEGFR3-Ig
591 mice and their WT littermates despite the increase in the number of cytotoxic T cells. As discussed
592 previously, this could be due to limitations in our analytical approach. However, it is also possible
593 that although triggered by cytotoxic T cells, secondary neurodegeneration and associated behavioral
594 correlates may appear at a later time point than the one analyzed in this study. Specific analyses
595 should be conducted in the K14-VEGFR3-Ig mice to assess the long-term effects of mLV deficits
596 on the progression of TBI pathology.

597

598 **Conclusions**

599 Our study investigated the phenotype of T lymphocytes infiltrating and persisting in the brain after
600 TBI, pointing to the activation of the CD8+ resident memory T cells in the early chronic response.

601 Our findings also support the importance of mLVs and dcLNs in maintaining brain immuno
602 tolerance. We, therefore, propose that the modulation of the neuro-immune response via the CNS-
603 lymphatic system, or by directly targeting the brain-resident memory T cells, could offer therapeutic
604 strategies for the treatment of TBI patients.

605

606 **Acknowledgments**

607 This study has been supported by the Academy of Finland (Academy of Finland research
608 Fellowship #309479/2017 – FMN; Academy of Finland research Project #314498 - KA), by the
609 Jane and Aatos Erkko Foundation (JK and KA), by the Finnish Brain Foundation Terva Program
610 (KA) and by European Research Council (ERC) under the European Union's Horizon 2020 research
611 and innovation programme under grant agreement #743155 (KA).

612 For their help with MRI sequences, the authors would like to thank Mikko Kettunen and Riikka
613 Immonen from Biomedical Imaging Unit, National Bio-NMR facility, A.I.Virtanen Institute for
614 Molecular Sciences, University of Eastern Finland. Authors thank also Carlton Wong, Flavia
615 Scoyni and Bengisan Dvirick for their contribution in performing experiments. Finally, authors
616 thank Dr. Nicola Marchi for his contribution in discussing the conclusions of this work.

617

618 **Author Contributions**

619 **SW**: Methodology, Investigation, Validation, Data Curation, Writing – Review and Editing; **MV**:
620 Investigation, Data curation, Formal analysis; **BG**: Software, Formal analysis; **AV**: Investigation,
621 Formal analysis; **MHK**: Investigation, Writing – Review and Editing; **SA**: Resources, Writing –
622 Review and Editing; **KA**: Supervision, Funding acquisition; **JEK**: Supervision, Funding
623 acquisition; **FMN**: Conceptualization, Methodology, Validation, Writing, Supervision, Funding
624 acquisition.

625

626 **Conflict of Interest Statement**

627 None of the authors have any conflict of interest to disclose. The authors confirm they have read the
628 Journal's position on issues involved in ethical publication and affirm that this report is consistent
629 with those guidelines.

630

631 **Data Availability**

632 The raw data supporting the conclusions of this manuscript will be made available by the
633 corresponding author, upon reasonable request, to any qualified researcher.

634

635 **Legend to Figures**

636 **Figure 1. Gating strategy.** Flow cytometry analysis scheme showing how isolated immune cells in
637 the brain were gated for live cell analysis. Mononuclear cells were discriminated out from debris
638 (red dotted line) by light scattering properties in a 2D plot showing forward scatter (FSC-A) vs. side
639 scatter (SSC-A) (A). These gated cells were analyzed further with Height (-H) and Area (-A)
640 parameters of FSC and SSC to remove cell doublets (B, C). From these single gated events, live
641 cells were defined as negative for near infrared fluorochrome-conjugated fixable viability dye
642 (FVD-NIR) (D), then from these live cells, T cells were identified as positive for TCR β (E). TCR β +
643 lymphocyte subsets were characterized by the expression of CD4 and CD8 cell surface markers (F).
644 Gating was determined using FMOs (see Methods section).

645 **Figure 2. Localization of CD3+ T cells in the perilesional cortices.** Representative images of brain
646 sections from WT CCI (A) and TG CCI (B) mice 30 dpi, stained for anti-CD3 ϵ (T lymphocytes;
647 red). The lesion edges in each section are marked with a segmented yellow line. T cells are present
648 within the lesion (star in A and B), in the perilesional cortex (box in A and panel C) and in the
649 corpus callosum (box in A and panel D). CD3+ cells were also observed in the striatum (arrow in A
650 and B) and in the thalamus (arrow head in A). Both scattered cells and clusters of T cells were
651 found within the parenchyma (C and E, respectively). Panels (C) and (D) represent a magnification
652 of the areas depicted within the white boxes in A. Panel (E) represents a magnification of the area
653 depicted within the white box in B. (A and B, scale bar = 500 μ m; C-E, scale bar = 20 μ m.)

654

655 **Figure 3. T cell brain infiltration is confined to the perilesional cortices, 30 dpi.** Box plot
656 representing the number of infiltrating T cells, defined by expression of TCR β (A) and stacked
657 bargram representing the percentage of CD4+ and CD8+ T cells (B) in the brain of WT and TG
658 mice, as analyzed in the perilesional and contralateral cortices (ipsi and contra, respectively), or in
659 intact cortices from respective naïve mice. Independently from the genotype, a significant

660 infiltration of TCR β ⁺ T cells was observed in the perilesional areas but not in the contralateral
661 hemispheres (comparable to naïve non-injured brains). The majority of brain-infiltrating T cells
662 presented a CD8 phenotype. In the TG CCI mice, there was a significant skew of CD4/CD8 ratio
663 towards CD8⁺ T cells. Table (C) summarizes the results of the statistical analysis in T cell counts
664 between the experimental groups. In (A) boxes represent the 25-75 % value range, including the
665 median value, indicated with the line. Whiskers represent 1.5x standard deviation (SD). □ indicates
666 the mean value. In the stacked bargram, data are presented as mean \pm standard error of the mean
667 (s.e.m.). A binomial negative regression or a linear mixed model was applied to assess statistical
668 differences in the counts of total T cells. The Kruskal Wallis test or the paired samples Wilcoxon
669 signed ranked test was used for the analysis of CD4 and CD8 frequency distribution. $\#p < 0.05$ and
670 $\#\#\#p < 0.001$ vs. TG ipsi. * $p < 0.05$ and *** $p < 0.001$ vs. WT ipsi. In all tests, Bonferroni correction
671 was used to adjust p-values in multiple comparisons.

672 **Figure 4. The number of CD4⁺ but not of CD8⁺ T cells is reduced in the brain of K14-VEGFR3-**
673 **Ig mice after TBI.** Box plots representing the number and frequency of CD4⁺ T cells (A and C,
674 respectively) and CD8⁺ T cells (B and D, respectively), in the brain of WT and TG mice, as
675 analyzed in the perilesional and contralateral cortices (ipsi and contra, respectively), or in intact
676 cortices from naïve mice. A drastic reduction in the number of CD4⁺ T cells was found in TG mice
677 after injury. A binomial negative regression or a linear mixed model was applied to assess statistical
678 differences in the counts of CD4⁺ and CD8⁺ T cells. The Kruskal Wallis test or the paired samples
679 Wilcoxon signed ranked test was used for the analysis of frequency distribution. * $p < 0.05$; ** $p <$
680 0.01 and *** $p < 0.001$ vs. WT ipsi. $\#p < 0.05$; $\#\#\#p < 0.01$ and $\#\#\#\#p < 0.001$ vs. TG ipsi. $\#p < 0.05$
681 vs. WT contra. In all tests, Bonferroni correction was used to adjust p-values in multiple
682 comparisons. For box plot explanation, refer to the legend of Figure 3.

683 **Figure 5. Analysis of CD69 and CD44 T cell activation and memory markers in CD4⁺ and CD8⁺**
684 **subpopulations.** Pseudocolor dot plots (A) and (B) represent gated subpopulations CD69 vs. CD44
685 of CD4⁺ and CD8⁺, respectively. Stacked bargrams in (C) and (D) show respectively the counts
686 and frequencies of CD8⁺ T cell subpopulations, as analyzed in the perilesional cortices of WT and
687 TG mice. No significant differences in CD8⁺ subpopulations were found between genotypes. In
688 CD4⁺ subpopulation, instead, we observed a significant reduction in the counts of CD44^{hi}CD69⁺
689 and CD44^{hi}CD69⁻ subpopulations (E), in K14-VEGFR3-Ig compared to WT mice. However, no
690 differences were observed in the different subpopulation frequencies (F). Data are presented as
691 mean \pm s.e.m. A binomial negative regression was applied to assess statistical differences in the

692 counts of total T cells between WT ipsi and TG ipsi. The Kruskal Wallis test was used for the
693 analysis of frequency distribution. #p < 0.05; *p < 0.05 vs. WT ipsi.

694 **Figure 6. TBI-induced lesions does not differ between the two genotypes, as inferred by the**
695 **analysis of MRI at 21 dpi.** (A) Representative MR images of WT naïve, WT CCI, TG naïve and
696 TG CCI brains. Perilesional cortices in WT CCI and TG CCI brains are marked with stars. (B)
697 Representative images of WT CCI and TG CCI brains stained for MAP2, NeuN and GFAP at 30
698 dpi. No differences in neuronal damage or in neuroinflammation were visible between the two
699 genotypes. Box plots in (C) and (D) illustrate the genotype effect on the percentage of contusion
700 volume and of brain atrophy, respectively, over the volume of the hemisphere ipsilateral to the
701 lesion. No significant differences were observed between K14-VEGFR3-Ig and WT mice. For the
702 definitions of the contusion volume and of brain atrophy see the main text. (D) When considering
703 the contusion volume and the brain atrophy independently from the genotype, we found a direct
704 correlation between the two parameters. The Kruskal Wallis test was used for the analysis of infarct
705 volume and of tissue loss between the two genotypes. CI: 95 % confidence interval. For box plot
706 explanation, refer to the legend of Figure 3.

707 **Figure 7. Peripheral immune response in the spleen.** The percentages of T cells in the spleen of
708 WT naïve and CCI mice and of TG naïve and CCI mice are presented in the box plot in panel (A).
709 Stacked bargrams in (B) represent the relative percentages of CD4 and CD8 in T cell population, in
710 WT and K14-VEGFR3-Ig mice. K14-VEGFR3-Ig mice present a drastic reduction of T cells
711 compared to WT littermates, due to a decrease in CD8+ T cell frequency. (C, D) Representative
712 pseudocolor dot plots and gating strategies for CD4+ and CD8+ T cell subpopulation analysis,
713 respectively. Stacked bargrams in (E) and (F) show respectively the frequencies of CD4+ and
714 CD8+ T cell subpopulations, as analyzed in WT and TG mice. Significant differences in the
715 frequencies of both CD4+ and CD8+ subpopulations have been observed. The Kruskal Wallis test
716 or the paired samples Wilcoxon signed ranked test was used for the analysis of frequency
717 distribution. $\#\#p < 0.01$ and $\#\#\#p < 0.001$ vs. TG CCI. $\#\#p < 0.01$ and $\#\#\#p < 0.001$ vs. WT naïve.
718 In all tests, Bonferroni correction was used to adjust p-values in multiple comparison. For box plot
719 and stacked bargram explanation, refer to the legend of Figure 3.

720

721 Bibliography

722 Antila, S., Karaman, S., Nurmi, H., Airavaara, M., Voutilainen, M.H., Mathivet, T., Chilov, D., Li,
723 Z., Koppinen, T., Park, J.H., Fang, S., Aspelund, A., Saarma, M., Eichmann, A., Thomas, J.L.,

- 724 Alitalo, K., 2017. Development and plasticity of meningeal lymphatic vessels. *J. Exp. Med.* 214,
725 3645-3667
- 726 Aspelund, A., Antila, S., Proulx, S.T., Karlsen, T.V., Karaman, S., Detmar, M., Wiig, H., Alitalo,
727 K., 2015. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules.
728 *J. Exp. Med.* 212, 991-999
- 729 Bai, R., Gao, H., Han, Z., Huang, S., Ge, X., Chen, F., Lei, P., 2017. Flow Cytometric
730 Characterization of T Cell Subsets and Microglia After Repetitive Mild Traumatic Brain Injury in
731 Rats. *Neurochem. Res.*
- 732 Bates, D., Machler, M., Bolker, B., Walker, S., 2015. Fitting Linear Mixed-Effects Models Using
733 lme4. *Journal of Statistical Software.* 67, 1-48
- 734 Braun, M., Vaibhav, K., Saad, N., Fatima, S., Brann, D.W., Vender, J.R., Wang, L.P., Hoda, M.N.,
735 Baban, B., Dhandapani, K.M., 2017. Activation of Myeloid TLR4 Mediates T Lymphocyte
736 Polarization after Traumatic Brain Injury. *J. Immunol.* 198, 3615-3626
- 737 Budd, R.C., Cerottini, J.C., Horvath, C., Bron, C., Pedrazzini, T., Howe, R.C., MacDonald, H.R.,
738 1987. Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1
739 glycoprotein concomitant with antigenic stimulation. *J. Immunol.* 138, 3120-3129
- 740 Clausen, F., Lorant, T., Lewen, A., Hillered, L., 2007. T lymphocyte trafficking: a novel target for
741 neuroprotection in traumatic brain injury. *J. Neurotrauma.* 24, 1295-1307
- 742 Clement, T., Lee, J.B., Ichkova, A., Rodriguez-Grande, B., Fournier, M.L., Aussudre, J., Ogier, M.,
743 Haddad, E., Canini, F., Koehl, M., Abrous, D.N., Obenaus, A., Badaut, J., 2019. Juvenile mild
744 traumatic brain injury elicits distinct spatiotemporal astrocyte responses. *Glia*
- 745 Cole, J.T., Yarnell, A., Kean, W.S., Gold, E., Lewis, B., Ren, M., McMullen, D.C., Jacobowitz,
746 D.M., Pollard, H.B., O'Neill, J.T., Grunberg, N.E., Dalgard, C.L., Frank, J.A., Watson, W.D., 2011.
747 Craniotomy: true sham for traumatic brain injury, or a sham of a sham?. *J. Neurotrauma.* 28, 359-
748 369
- 749 Cserr, H.F., Harling-Berg, C.J., Knopf, P.M., 1992. Drainage of brain extracellular fluid into blood
750 and deep cervical lymph and its immunological significance. *Brain Pathol.* 2, 269-276
- 751 Czigner, A., Mihaly, A., Farkas, O., Buki, A., Krisztin-Peva, B., Dobo, E., Barzo, P., 2007. Kinetics
752 of the cellular immune response following closed head injury. *Acta Neurochir. (Wien).* 149, 281-
753 289
- 754 Daglas, M., Draxler, D.F., Ho, H., McCutcheon, F., Galle, A., Au, A.E., Larsson, P., Gregory, J.,
755 Alderuccio, F., Sashindranath, M., Medcalf, R.L., 2019. Activated CD8(+) T Cells Cause Long-
756 Term Neurological Impairment after Traumatic Brain Injury in Mice. *Cell. Rep.* 29, 1178-1191.e6
- 757 DeKosky, S.T., Kochanek, P.M., Clark, R.S., Ciallella, J.R., Dixon, C.E., 1998. Secondary Injury
758 After Head Trauma: Subacute and Long-term Mechanisms. *Semin. Clin. Neuropsychiatry.* 3, 176-
759 185

- 760 Dewan, M.C., Rattani, A., Gupta, S., Baticulon, R.E., Hung, Y.C., Punchak, M., Agrawal, A.,
761 Adeleye, A.O., Shrimel, M.G., Rubiano, A.M., Rosenfeld, J.V., Park, K.B., 2018. Estimating the
762 global incidence of traumatic brain injury. *J. Neurosurg.*, 1-18
- 763 Dhungana, H., Rolova, T., Savchenko, E., Wojciechowski, S., Savolainen, K., Ruotsalainen, A.K.,
764 Sullivan, P.M., Koistinaho, J., Malm, T., 2013. Western-type diet modulates inflammatory
765 responses and impairs functional outcome following permanent middle cerebral artery occlusion in
766 aged mice expressing the human apolipoprotein E4 allele. *J. Neuroinflammation.* 10, 102-2094-10-
767 102
- 768 Dressler, J., Hanisch, U., Kuhlisch, E., Geiger, K.D., 2007. Neuronal and glial apoptosis in human
769 traumatic brain injury. *Int. J. Legal Med.* 121, 365-375
- 770 Erturk, A., Mentz, S., Stout, E.E., Hedehus, M., Dominguez, S.L., Neumaier, L., Krammer, F.,
771 Llovera, G., Srinivasan, K., Hansen, D.V., Liesz, A., Scearce-Levie, K.A., Sheng, M., 2016.
772 Interfering with the Chronic Immune Response Rescues Chronic Degeneration After Traumatic
773 Brain Injury. *J. Neurosci.* 36, 9962-9975
- 774 Fee, D., Crumbaugh, A., Jacques, T., Herdrich, B., Sewell, D., Auerbach, D., Piaskowski, S., Hart,
775 M.N., Sandor, M., Fabry, Z., 2003. Activated/effector CD4+ T cells exacerbate acute damage in the
776 central nervous system following traumatic injury. *J. Neuroimmunol.* 136, 54-66
- 777 Fernandez-Klett, F., Priller, J., 2014. The fibrotic scar in neurological disorders. *Brain Pathol.* 24,
778 404-413
- 779 Galea, I., Bechmann, I., Perry, V.H., 2007. What is immune privilege (not)? *Trends Immunol.* 28,
780 12-18
- 781 Gasper, D.J., Tejera, M.M., Suresh, M., 2014. CD4 T-cell memory generation and maintenance.
782 *Crit. Rev. Immunol.* 34, 121-146
- 783 GBD 2016 Neurology Collaborators, 2019. Global, regional, and national burden of neurological
784 disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*
785 *Neurol.* 18, 459-480
- 786 Gebhardt, T., Wakim, L.M., Eidsmo, L., Reading, P.C., Heath, W.R., Carbone, F.R., 2009. Memory
787 T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes
788 simplex virus. *Nat. Immunol.* 10, 524-530
- 789 Graham, N.S., Sharp, D.J., 2019. Understanding neurodegeneration after traumatic brain injury:
790 from mechanisms to clinical trials in dementia. *J. Neurol. Neurosurg. Psychiatry.* 90, 1221-1233
- 791 Guedel, A.E., 1927. Stages of Anesthesia and re-classification of the signs of anesthesia. *Current*
792 *Researches in Anesthesia & Analgesia.* 6, 157-162
- 793 Hale, A.C., Bohnert, K.M., Grekin, R., Sripada, R.K., 2019. Traumatic Brain Injury in the General
794 Population: Incidence, Mental Health Comorbidity, and Functional Impact. *J. Nerv. Ment. Dis.* 207,
795 38-42

- 796 Harling-Berg, C.J., Park, T.J., Knopf, P.M., 1999. Role of the cervical lymphatics in the Th2-type
797 hierarchy of CNS immune regulation. *J. Neuroimmunol.* 101, 111-127
- 798 Hausmann, R., Kaiser, A., Lang, C., Bohnert, M., Betz, P., 1999. A quantitative
799 immunohistochemical study on the time-dependent course of acute inflammatory cellular response
800 to human brain injury. *Int. J. Legal Med.* 112, 227-232
- 801 Holmin, S., Soderlund, J., Biberfeld, P., Mathiesen, T., 1998. Intracerebral inflammation after
802 human brain contusion. *Neurosurgery.* 42, 291-8; discussion 298-9
- 803 Hothorn, T., Bretz, F., Westfall, P., 2008. Simultaneous Inference in General Parametric Models.
804 *Biometrical Journal.* 50, 346-363
- 805 Hutchinson, E., Avery, A., Vandewoude, S., 2005. Environmental enrichment for laboratory
806 rodents. *ILAR J.* 46, 148-161
- 807 Hyder, A.A., Wunderlich, C.A., Puvanachandra, P., Gururaj, G., Kobusingye, O.C., 2007. The
808 impact of traumatic brain injuries: a global perspective. *NeuroRehabilitation.* 22, 341-353
- 809 Immonen, R., Heikkinen, T., Tahtivaara, L., Nurmi, A., Stenius, T.K., Puolivali, J., Tuinstra, T.,
810 Phinney, A.L., Van Vliet, B., Yrjanheikki, J., Grohn, O., 2010. Cerebral blood volume alterations in
811 the perilesional areas in the rat brain after traumatic brain injury--comparison with behavioral
812 outcome. *J. Cereb. Blood Flow Metab.* 30, 1318-1328
- 813 Immonen, R.J., Kharatishvili, I., Grohn, H., Pitkanen, A., Grohn, O.H., 2009. Quantitative MRI
814 predicts long-term structural and functional outcome after experimental traumatic brain injury.
815 *Neuroimage.* 45, 1-9
- 816 Immonen, R.J., Kharatishvili, I., Niskanen, J.P., Grohn, H., Pitkanen, A., Grohn, O.H., 2009.
817 Distinct MRI pattern in lesional and perilesional area after traumatic brain injury in rat--11 months
818 follow-up. *Exp. Neurol.* 215, 29-40
- 819 Jin, X., Ishii, H., Bai, Z., Itokazu, T., Yamashita, T., 2012. Temporal changes in cell marker
820 expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6
821 mice. *PLoS One.* 7, e41892
- 822 Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F.,
823 Arbour, N., Becher, B., Prat, A., 2007. Human TH17 lymphocytes promote blood-brain barrier
824 disruption and central nervous system inflammation. *Nat. Med.* 13, 1173-1175
- 825 Kelso, M.L., Gendelman, H.E., 2014. Bridge between neuroimmunity and traumatic brain injury.
826 *Curr. Pharm. Des.* 20, 4284-4298
- 827 Louveau, A., Herz, J., Alme, M.N., Salvador, A.F., Dong, M.Q., Viar, K.E., Herod, S.G., Knopp, J.,
828 Setliff, J.C., Lupi, A.L., Da Mesquita, S., Frost, E.L., Gaultier, A., Harris, T.H., Cao, R., Hu, S.,
829 Lukens, J.R., Smirnov, I., Overall, C.C., Oliver, G., Kipnis, J., 2018. CNS lymphatic drainage and
830 neuroinflammation are regulated by meningeal lymphatic vasculature. *Nat. Neurosci.* 21, 1380-
831 1391

- 832 Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C.,
833 Castle, D., Mandell, J.W., Lee, K.S., Harris, T.H., Kipnis, J., 2015. Structural and functional
834 features of central nervous system lymphatic vessels. *Nature*. 523, 337-341
- 835 Maegele, M., Stuermer, E.K., Hoeffgen, A., Uhlenkueken, U., Mautes, A., Schaefer, N., Lippert-
836 Gruener, M., Schaefer, U., Hoehn, M., 2015. Multimodal MR imaging of acute and subacute
837 experimental traumatic brain injury: Time course and correlation with cerebral energy metabolites.
838 *Acta Radiol. Short Rep.* 4, 2047981614555142
- 839 Makinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M.I., Pulkkanen, K.J., Kauppinen,
840 R., Jackson, D.G., Kubo, H., Nishikawa, S., Yla-Herttuala, S., Alitalo, K., 2001. Inhibition of
841 lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF
842 receptor-3. *Nat. Med.* 7, 199-205
- 843 McIntosh, T.K., Smith, D.H., Meaney, D.F., Kotapka, M.J., Gennarelli, T.A., Graham, D.I., 1996.
844 Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and
845 biomechanical mechanisms. *Lab. Invest.* 74, 315-342
- 846 Mendiburu, F.d., 2019. *agricolae: Statistical Procedures for Agricultural Research*
- 847 Menon, D.K., Schwab, K., Wright, D.W., Maas, A.I., Demographics and Clinical Assessment
848 Working Group of the International and Interagency Initiative toward Common Data Elements for
849 Research on Traumatic Brain Injury and Psychological Health, 2010. Position statement: definition
850 of traumatic brain injury. *Arch. Phys. Med. Rehabil.* 91, 1637-1640
- 851 Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I.R., Schwartz, M., 1999. Autoimmune
852 T cells protect neurons from secondary degeneration after central nervous system axotomy. *Nat.*
853 *Med.* 5, 49-55
- 854 Ponta, H., Sherman, L., Herrlich, P.A., 2003. CD44: from adhesion molecules to signalling
855 regulators. *Nat. Rev. Mol. Cell Biol.* 4, 33-45
- 856 Revelle, W, 2018. *psych: Procedures for Psychological, Psychometric, and Personality Research.*
857 Northwestern University, Evanston, Illinois
- 858 Roederer, M., 2002. Compensation in flow cytometry. *Curr. Protoc. Cytom.* Chapter 1, Unit 1.14
- 859 Sashindranath, M., Daglas, M., Medcalf, R.L., 2015. Evaluation of gait impairment in mice
860 subjected to craniotomy and traumatic brain injury. *Behav. Brain Res.* 286, 33-38
- 861 Schumann, J., Stanko, K., Schliesser, U., Appelt, C., Sawitzki, B., 2015. Differences in CD44
862 Surface Expression Levels and Function Discriminates IL-17 and IFN-gamma Producing Helper T
863 Cells. *PLoS One.* 10, e0132479
- 864 Schwartz, M., Raposo, C., 2014. Protective Autoimmunity: A Unifying Model for the Immune
865 Network Involved in CNS Repair. *Neuroscientist.* 20, 343-358
- 866 Shuaib, A., Xu Wang, C., Yang, T., Noor, R., 2002. Effects of nonpeptide V(1) vasopressin
867 receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic
868 stroke model. *Stroke.* 33, 3033-3037

- 869 Thomas, D.L., Kranz, D.M., Roy, E.J., 2008. Experimental manipulations of afferent immune
870 responses influence efferent immune responses to brain tumors. *Cancer Immunol. Immunother.* 57,
871 1323-1333
- 872 Thomas, S.N., Rutkowski, J.M., Pasquier, M., Kuan, E.L., Alitalo, K., Randolph, G.J., Swartz,
873 M.A., 2012. Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal
874 lymphatic drainage. *J. Immunol.* 189, 2181-2190
- 875 Topham, D.J., Reilly, E.C., 2018. Tissue-Resident Memory CD8(+) T Cells: From Phenotype to
876 Function. *Front. Immunol.* 9, 515
- 877 Tsunoda, I., 2017. Lymphatic system and gut microbiota affect immunopathology of
878 neuroinflammatory diseases, including multiple sclerosis, neuromyelitis optica and Alzheimer's
879 disease. *Clin. Exp. Neuroimmunol.* 8, 177-179
- 880 Venables, W N, Ripley, B.D., 2002. *Modern Applied Statistics with S*, Fourth ed. Springer, New
881 York
- 882 Weckbach, S., Neher, M., Losacco, J.T., Bolden, A.L., Kulik, L., Flierl, M.A., Bell, S.E., Holers,
883 V.M., Stahel, P.F., 2012. Challenging the role of adaptive immunity in neurotrauma: Rag1(-/-) mice
884 lacking mature B and T cells do not show neuroprotection after closed head injury. *J. Neurotrauma.*
885 29, 1233-1242
- 886 Yasmin, A., Pitkanen, A., Jokivarsi, K., Poutiainen, P., Grohn, O., Immonen, R., 2019. MRS
887 Reveals Chronic Inflammation in T2w MRI-Negative Perilesional Cortex - A 6-Months Multimodal
888 Imaging Follow-Up Study. *Front. Neurosci.* 13, 863
- 889 Ziegler, S.F., Ramsdell, F., Alderson, M.R., 1994. The activation antigen CD69. *Stem Cells.* 12,
890 456-465
- 891

Figure 1

bioRxiv preprint doi: <https://doi.org/10.1101/821645>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure 2





Figure 3



C

TCRβ+ cells (counts)

Comparisons (within WT)	p-value	Comparisons (within TG)	p-value	Comparisons (between genotypes)	p-value
ipsi vs. naïve	<0.0001 (***) ^a	ipsi vs. naïve	<0.0001 (****) ^a	naïve (WT vs. TG)	1.0000 ^a
ipsi vs. contra	0.0112 (*) ^b	ipsi vs. contra	0.0151 (**) ^b	ipsi (WT vs. TG)	1.0000 ^a
contra vs. naïve	1.0000 ^a	contra vs. naïve	1.0000 ^a	contra (WT vs. TG)	1.0000 ^a

^a by Kruskal Wallis test, followed by Bonferroni correction

^b by paired samples Wilcoxon signed rank test, followed by Bonferroni correction

Figure 4




Figure 5

bioRxiv preprint doi: <https://doi.org/10.1101/821645>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure 6




Figure 7

